Small Business Innovative Research Program (SBIR) Competing Renewal Awards for Drug Development in Mental Health

Notice Number: NOT-MH-07-118

Key Dates
Release Date: August 23, 2007

Issued by
National Institute of Mental Health (NIMH) (

The purpose of this Notice is to inform the small business research community that NIMH is increasing the budget limit for the specific Funding Opportunity Announcement (FOA), PA-06-079, entitled Competing Renewal Awards of SBIR Phase II Grants for Pharmacologic Agents and Drugs for Mental Disorders (SBIR R43/R44).

The current budget allowance described in that FOA is up to $800,000 total costs per year for up to three years. Due to increasing difficulty for small businesses to receive outside funding for high risk drug development projects, NIMH has increased the funds available for this funding opportunity, such that budgets up to $1.0 million total costs per year will be allowed. The duration of awards for the Phase II competing renewal award will remain at up to 3 years. Total costs include direct costs, F&A, and fee/profit. Grant applications that do not focus on drug development, but that require federal regulatory approval prior to commercialization, will continue to have budget limits of up to $800,000 total costs per year and time periods up to 3 years for the Phase II competing renewal award.

Additional information

For more information on this FOA, please see:
For more information on the NIH SBIR program, please see:


Inquiries regarding this Notice should be directed to:

Margaret Grabb, Ph.D.
National Institute of Mental Health
6001 Executive Boulevard, Room 7201, MSC 9645
Bethesda, MD 20892-9645
Rockville, MD 20852 (for express or courier service)
Telephone: (301) 443-3563